Microbiologic treatment failure was found to be independently associated with recurrent pneumonia or death among patients with bacterial pneumonia after clinical cure.
Inhaled amikacin adjunctive to standard-of-care intravenous antibiotic therapy was not associated with improvements in survival in mechanically ventilated patients with Gram-negative pneumonia.
Biomarker-guided exclusion of ventilator-associated pneumonia was not associated with a reduction in antibiotic use.
Exposure to carbapenem and carboxypenicillin or ureidopenicillin during the week before onset of ventilator-associated pneumonia and the severity of disease with regard to respiratory and hematologic failures were independent risk factors for the occurrence of Stenotrophomonas maltophilia-related VAP.
The incidence of invasive pneumococcal disease (IPD) is >7-times higher in people living with HIV (PLWHIV) compared with the general population.